A Randomized, Double-Blind, Parallel-Controlled Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of SCT510 to Bevacizumab (Avastin(®)) in Healthy Chinese Males

BACKGROUND: SCT510 is a recombinant humanized monoclonal antibody targeting vascular endothelial growth factor (VEGF), which is intended as a candidate biosimilar of bevacizumab that is approved for various metastatic cancers.Please confirm change in wording to match definition for VEGF belowYes. OB...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Jing, Wu, Guolan, Xie, Liangzhi, Lv, Duo, Xu, Chang, Zhou, Huili, Wu, Lihua, Zhang, Jingjing, Shentu, Jianzhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10293153/
https://www.ncbi.nlm.nih.gov/pubmed/37247166
http://dx.doi.org/10.1007/s40268-023-00424-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10293153/
https://www.ncbi.nlm.nih.gov/pubmed/37247166
http://dx.doi.org/10.1007/s40268-023-00424-8

Ejemplares similares